Altre lingue Lundbeck Nasdaq Copenhagen

Azioni

LUN

DK0061804697

Mercato chiuso - Nasdaq Copenhagen Altri mercati azionari 17:20:00 05/07/2024			Variaz. 5gg	Var. 1 gen.
34,2 ^DKK	+0,29%		+2,40%	-0,98%

26/06	Il trattamento PTSD di Otsuka e Lundbeck avanza con l'accettazione da parte della FDA della richiesta di un nuovo farmaco	MT
25/06	La FDA statunitense accetta la richiesta di nuovi farmaci di Lundbeck e Otsuka per il trattamento combinato del PTSD	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	26/06
US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	25/06
Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)	25/06
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder	25/06
Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial	19/06
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial	19/06
Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia	03/06
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia	03/06
H LUNDBECK : Q1 beat adds momentum to the recent share price rally	15/05
Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024	15/05
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	15/05
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	13/05
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck	13/05
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	13/05
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	09/04
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	09/04
Lundbeck : Articles of Association	02/04
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

H LUNDBECK : La battuta del 1° trimestre aggiunge slancio al recente rally del prezzo dell'azione

15 maggio 2024 alle 18:20